Publications by authors named "Yasunobu Kouki"
Article Synopsis
- - The study examined the role of programmed cell death-ligand 1 (PD-L1) expression and epidermal growth factor receptor (EGFR) mutations as biomarkers for lung adenocarcinoma, analyzing data from 847 patients across 21 centers in Japan from 2015 to 2018.
- - Results showed that while PD-L1 expression was linked to shorter recurrence-free survival (RFS) in both EGFR-mutant and wild-type patients, it had no effect on overall survival (OS) in EGFR-mutant patients.
- - The findings suggest that PD-L1 expression is a poor predictor of OS for EGFR-mutant patients and does not influence the effectiveness of post-relapse treatment with EGFR-
Article Synopsis
- - The study analyzed the effects of central nervous system (CNS) metastasis on performance status, treatment responses, and survival rates in lung adenocarcinoma patients with common EGFR mutations following surgical resection.
- - Out of 4181 patients, 78 experienced CNS metastasis, which was more common in those receiving conventional adjuvant chemotherapy; however, this treatment showed no significant benefits in relapse-free survival or overall survival post-relapse.
- - The findings suggest that CNS metastasis doesn't noticeably impact performance status or alter treatment efficacy with EGFR-tyrosine kinase inhibitors, indicating a need for more studies on managing CNS metastasis in the context of adjuvant TKI therapies.
Article Synopsis
- HIF-PHI, specifically roxadustat, is a new treatment for renal anemia that works by boosting erythropoietin levels but has raised concerns about potential side effects, particularly hypothyroidism.
- A study found a significant link between roxadustat use and hypothyroidism in real-world scenarios, while another HIF-PHI, daprodustat, did not show these signals.
- Patients using roxadustat should be monitored for thyroid function changes, as around 50% of hypothyroidism cases appeared within the first 50 days of treatment, regardless of the patient's age or sex.
Background: This phase I study aimed to evaluate the safety, peptide-specific immune responses, and anti-tumor effects of a novel vaccination therapy comprising multi-HLA-binding heat shock protein (HSP) 70/glypican-3 (GPC3) peptides and a novel adjuvant combination of hLAG-3Ig and Poly-ICLC against metastatic gastrointestinal cancers.
Methods: HSP70/GPC3 peptides with high binding affinities for three HLA types (A*24:02, A*02:01, and A*02:06) were identified with our peptide prediction system. The peptides were intradermally administered with combined adjuvants on a weekly basis.